Streetbeat News

Regulatory

IRTC

iRhythm Technologies received a warning letter from the FDA on May 25, alleging non-conformities to regulations for medical devices related to the company's Zio AT System.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 8:23 pm

ATAK

ATAKU

Aurora Technology Acquisition Corp. received a notice of deficiency from Nasdaq due to a delayed quarterly report on Form 10-Q. The company has now filed the Form 10-Q with the SEC and submitted a plan of compliance to Nasdaq.

Portfolio Pulse from Happy Mohamed

May 30, 2023 | 8:22 pm

GLNCY

OR

Osisko Gold Royalties' subsidiary Osisko Bermuda Limited and Glencore have received approval from the Australian Foreign Investment Review Board for their investment in Metals Acquisition Corporation, as part of the proposed acquisition of the CSA Copper Mine.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 8:18 pm

CLVR

Clever Leaves Holdings Inc. (NASDAQ:CLVR) has completed its first shipment of medical cannabis extracts from Colombia to Astrasana Holding AG in Switzerland, marking its entry into the Swiss market. The strategic partnership and supply agreement between Clever Leaves and Astrasana will ensure a consistent supply of medical cannabis extracts at competitive prices and expand Clever Leaves' presence in new European markets.

Portfolio Pulse from Joana Scopel

May 30, 2023 | 8:12 pm

ANIK

Anika Therapeutics has completed enrollment in its Hyalofast U.S. Pivotal Phase III study, a key step in the development of the biodegradable hyaluronic acid-based scaffold for cartilage repair.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 8:08 pm

PEPG

PepGen Inc. announces a clinical hold in the US on its IND application to initiate a Phase 1 study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1).

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 8:06 pm

CMPS

NUMIF

Numinus Wellness' Cedar Clinical Research has joined COMPASS Pathways' Phase 3 program studying psilocybin therapy for Treatment-Resistant Depression (TRD). The trial is part of the largest-ever international clinical program assessing psilocybin therapy, enrolling over 800 participants. Topline data from the Phase 3 clinical program is expected in summer 2024 and mid-2025.

Portfolio Pulse from Lara Goldstein

May 30, 2023 | 8:06 pm

FXI

SPY

The U.S. Commerce Department and its partners reviewed 5,064 export and reexport license applications for China in 2022, with approximately 26% being denied or returned without action, according to Senate testimony.

Portfolio Pulse from Happy Mohamed

May 30, 2023 | 8:05 pm

LATG

LatAmGrowth SPAC (LATG) has received a Nasdaq notification of noncompliance with Listing Rule 5250(c)(1). The company has 60 days, until July 24, 2023, to submit a plan to regain compliance with Nasdaq's listing requirements.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 8:03 pm

MRTX

Mirati Therapeutics will present encore data at the 2023 ASCO Annual Meeting, demonstrating adagrasib's potential as a targeted treatment for KRASG12C-mutated advanced solid tumors. The data follows the recent inclusion of adagrasib in NCCN Guidelines for PDAC and CNS Cancers.

Portfolio Pulse from Happy Mohamed

May 30, 2023 | 8:02 pm